Engitix Therapeutics
PrivateLast Round
Series A
Extension
Jan 8, 2026
Total Funding Raised
$86M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Engitix Therapeutics operates in Healthcare & Life Sciences and is based in London. Its latest recorded funding round was a Series A Extension round in January 2026.
Engitix Therapeutics is a biotechnology company that develops therapies for cancer and fibrosis by targeting the extracellular matrix (ECM).
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Engitix Therapeutics Comparables
Compare Engitix Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Apmonia Therapeutics | 76% | |
| Symic Bio | 76% | |
| Telescope Therapeutics | 69% |
For institutional investors. Book with your work email.
Engitix Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Jan 8, 2026 | ||||
| Series A | Jan 19, 2022 | ||||
| Seed | Nov 27, 2018 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Engitix Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Netherton Investments | Seed, Series A, Series A Extension |
| UCL Business | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 20, 2026
Monthly visitors increased 34% MoM, reaching 4.3K.
- Jul 24, 2026
Monthly visitors increased 270% MoM, reaching 3.2K.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- hiresOct 14, 2026
Engitix appoints Ryan Richardson to its Board of Directors as an Independent Non-Executive Director in United Kingdom on Oct 14th '26, as it advances its pipeline toward clinical development.
- hiresOct 14, 2026
Engitix welcomes Ryan to its Board on Oct 14th '26, drawing on his experience in biotechnology strategy, capital markets, corporate development and AI.
- hiresSep 23, 2026
Engitix appoints Sonia as EVP Chief Medical Officer, giving her responsibility for the company’s clinical and medical strategy after she serves as an independent non-executive director on its board since 2023.
- hiresSep 23, 2026
On Sep 23rd '26 in the United Kingdom, Engitix appoints Sonia Quaratino, MD, PhD to the newly created Executive Vice President Chief Medical Officer role, where she oversees the company’s clinical and medical strategy after serving as an independent non-executive director since 2023.
For institutional investors. Book with your work email.
Engitix Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Engitix Therapeutics's valuation, stock price, and market status.
Is Engitix Therapeutics a public or private company?
Engitix Therapeutics is a private company.
What is the current stock price of Engitix Therapeutics?
Engitix Therapeutics is a private company, so its shares have no public market price. Caplight tracks Engitix Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Engitix Therapeutics worth (valuation)?
Valuation information for Engitix Therapeutics is not publicly available.
Can I buy Engitix Therapeutics stock?
Engitix Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Engitix Therapeutics's last funding round?
Engitix Therapeutics's most recent funding round was Series A Extension on January 8, 2026.
Who are the main investors in Engitix Therapeutics?
Key investors in Engitix Therapeutics include Netherton Investments.
Will Engitix Therapeutics IPO soon?
No public IPO plans have been announced for Engitix Therapeutics.
How can I track Engitix Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Engitix Therapeutics's shares on secondary markets.